Biopharmaceutical company RedHill Biopharma has announced that the preliminary results from a preclinical study with a new oral drug, opaganib, showed a reduction of thrombosis (blood clotting) in an acute respiratory distress syndrome (ARDS) in the animal model.

Opaganib is an orally administered sphingosine kinase 2 (SK2) selective inhibitor.

It targets a host cell component, lowering the chances for resistance arising from viral mutations.

The preclinical study analysed 250mg/kg of opaganib to measure thrombotic risks.

ARDS-induced thrombosis may happen in up to one-third of Covid-19 patients needing ICU admission and is a major cause of death.

The latest data showed the possible benefit of opaganib to Covid-19 patients apart from the already established inhibition of SARS-CoV-2 replication, as well as potential reduction in hyper immune-response by opaganib.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

RedHill plans to analyse different physiologically and pharmacologically relevant opaganib doses that can reduce thrombosis.

RedHill R&D senior vice-president Reza Fathi said: “Results from our study show opaganib 250mg/kg reduced blood clot length, weight and total thrombus score in a preclinical model of ARDS.

“This adds to the known antiviral and anti-inflammatory activities of opaganib and provides the potential for a unique triple-action effect on the pathophysiological processes associated with Covid-19 disease.”

RedHill is carrying out a Phase II study assessing safety and potential efficacy signals of opaganib in patients with severe Covid-19 pneumonia in the US.

It has enrolled 40 subjects with the last patient receiving the final dose and expects top-line data later this month.

In addition, a global Phase II/III study of opaganib on 270 patients with severe Covid-19 pneumonia has enrolled more than 60% of patients.

It is approved in six countries and could deliver top-line data in the first quarter of next year.

In July, RedHill submitted an application to Mexico’s COFEPRIS and initiated a filing with Brazil’s ANVISA to conduct a Phase II/III trial of opaganib in hospitalised patients with severe Covid-19 pneumonia.

Clinical Trials Arena Excellence Awards - Have you nominated?

Nominations are now open for the prestigious Clinical Trials Arena Excellence Awards - one of the industry's most recognised programmes celebrating innovation, leadership, and impact. This is your chance to showcase your achievements, highlight industry advancements, and gain global recognition. Don't miss the opportunity to be honoured among the best - submit your nomination today!

Nominate Now